Walter & Keenan Financial Consulting Co. MI ADV cut its holdings in Bristol-Myers Squibb Company (NYSE:BMY) by 5.1% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,450 shares of the biopharmaceutical company’s stock after selling 450 shares during the quarter. Walter & Keenan Financial Consulting Co. MI ADV’s holdings in Bristol-Myers Squibb were worth $471,000 as of its most recent SEC filing.
A number of other large investors have also added to or reduced their stakes in the stock. Toronto Dominion Bank raised its holdings in Bristol-Myers Squibb by 54.0% in the first quarter. Toronto Dominion Bank now owns 464,591 shares of the biopharmaceutical company’s stock worth $25,264,000 after purchasing an additional 162,884 shares in the last quarter. Mutual of America Capital Management LLC raised its holdings in Bristol-Myers Squibb by 1.9% in the first quarter. Mutual of America Capital Management LLC now owns 201,037 shares of the biopharmaceutical company’s stock worth $10,932,000 after purchasing an additional 3,833 shares in the last quarter. Quantitative Investment Management LLC bought a new position in Bristol-Myers Squibb in the first quarter worth about $6,150,000. Meridian Management Co. raised its holdings in Bristol-Myers Squibb by 1.5% in the first quarter. Meridian Management Co. now owns 51,770 shares of the biopharmaceutical company’s stock worth $2,815,000 after purchasing an additional 770 shares in the last quarter. Finally, Tobam raised its holdings in Bristol-Myers Squibb by 124.5% in the first quarter. Tobam now owns 793,714 shares of the biopharmaceutical company’s stock worth $43,163,000 after purchasing an additional 440,170 shares in the last quarter. 68.84% of the stock is owned by institutional investors.
A number of equities analysts have commented on the stock. Citigroup Inc. boosted their target price on shares of Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a report on Wednesday. Jefferies Group LLC downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $72.00 target price for the company. in a report on Monday, October 16th. Barclays PLC boosted their target price on shares of Bristol-Myers Squibb from $58.00 to $65.00 and gave the stock an “equal weight” rating in a report on Friday, October 13th. BMO Capital Markets set a $49.00 target price on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a report on Thursday, October 12th. Finally, Vetr upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $67.92 target price for the company in a report on Monday, October 9th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and ten have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $63.79.
Shares of Bristol-Myers Squibb Company (BMY) opened at 64.42 on Friday. Bristol-Myers Squibb Company has a 12 month low of $46.01 and a 12 month high of $66.10. The company has a 50-day moving average price of $63.37 and a 200-day moving average price of $57.29. The stock has a market cap of $105.64 billion, a price-to-earnings ratio of 23.53 and a beta of 1.19.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 EPS for the quarter, topping the consensus estimate of $0.73 by $0.01. The company had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The firm’s revenue was up 5.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.69 earnings per share. On average, analysts expect that Bristol-Myers Squibb Company will post $2.99 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th will be given a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 2.42%. The ex-dividend date is Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 56.73%.
In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 9,340 shares of Bristol-Myers Squibb stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total transaction of $560,400.00. Following the transaction, the senior vice president now owns 46,297 shares of the company’s stock, valued at $2,777,820. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Theodore R. Samuels II purchased 6,000 shares of the business’s stock in a transaction on Wednesday, August 2nd. The shares were purchased at an average cost of $55.94 per share, for a total transaction of $335,640.00. Following the transaction, the director now owns 18,000 shares of the company’s stock, valued at $1,006,920. The disclosure for this purchase can be found here. Insiders own 0.23% of the company’s stock.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.